Repligen Corporation (RGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Repligen Corporation (RGEN) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($48.10 Million) by net assets ($2.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check RGEN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Repligen Corporation - Cash Flow Conversion Efficiency Trend (1990–2024)
This chart illustrates how Repligen Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Repligen Corporation (RGEN) shareholders funds for net asset value and shareholders' equity analysis.
Repligen Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repligen Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Abbott India Limited
NSE:ABBOTINDIA
|
0.130x |
|
Archrock Inc
NYSE:AROC
|
0.122x |
|
SmartSens Technology (Shanghai) Co. Ltd. A
SHG:688213
|
N/A |
|
WPG Holdings Ltd
TW:3702
|
0.192x |
|
ASX Ltd
AU:ASX
|
-0.346x |
|
Valaris Ltd
NYSE:VAL
|
0.024x |
|
Castellum AB
ST:CAST
|
0.015x |
|
OneMain Holdings Inc
NYSE:OMF
|
0.254x |
Annual Cash Flow Conversion Efficiency for Repligen Corporation (1990–2024)
The table below shows the annual cash flow conversion efficiency of Repligen Corporation from 1990 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Repligen Corporation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.97 Billion | $175.39 Million | 0.089x | +53.85% |
| 2023-12-31 | $1.97 Billion | $113.92 Million | 0.058x | -35.83% |
| 2022-12-31 | $1.91 Billion | $172.08 Million | 0.090x | +32.43% |
| 2021-12-31 | $1.75 Billion | $119.02 Million | 0.068x | +66.06% |
| 2020-12-31 | $1.53 Billion | $62.62 Million | 0.041x | -35.43% |
| 2019-12-31 | $1.06 Billion | $67.22 Million | 0.063x | +103.79% |
| 2018-12-31 | $-19.60 Million | $32.77 Million | -1.672x | -201.82% |
| 2017-12-31 | $-31.51 Million | $17.45 Million | -0.554x | -1342.81% |
| 2016-12-31 | $168.76 Million | $7.52 Million | 0.045x | -63.66% |
| 2015-12-31 | $122.75 Million | $15.05 Million | 0.123x | +154.64% |
| 2014-12-31 | $-81.99 Million | $18.40 Million | -0.224x | -189.92% |
| 2013-12-31 | $103.89 Million | $25.93 Million | 0.250x | +56.24% |
| 2012-12-31 | $84.12 Million | $13.44 Million | 0.160x | +356.45% |
| 2011-12-31 | $66.00 Million | $2.31 Million | 0.035x | -27.35% |
| 2010-12-31 | $67.09 Million | $3.23 Million | 0.048x | +230.28% |
| 2009-12-31 | $66.21 Million | $-2.45 Million | -0.037x | -140.13% |
| 2008-12-31 | $68.46 Million | $6.31 Million | 0.092x | -84.62% |
| 2007-12-31 | $64.21 Million | $38.47 Million | 0.599x | +3496.62% |
| 2006-12-31 | $24.34 Million | $405.48K | 0.017x | +0.50% |
| 2005-12-31 | $25.06 Million | $415.38K | 0.017x | +150.94% |
| 2004-12-31 | $24.44 Million | $-795.28K | -0.033x | +85.04% |
| 2003-12-31 | $26.30 Million | $-5.72 Million | -0.217x | -25.49% |
| 2002-12-31 | $30.34 Million | $-5.26 Million | -0.173x | +2.07% |
| 2001-12-31 | $26.87 Million | $-4.75 Million | -0.177x | -12.91% |
| 2000-12-31 | $29.48 Million | $-4.62 Million | -0.157x | -75.15% |
| 1999-12-31 | $35.03 Million | $-3.13 Million | -0.089x | +70.15% |
| 1998-12-31 | $4.00 Million | $-1.20 Million | -0.300x | -126.98% |
| 1997-12-31 | $5.30 Million | $-700.00K | -0.132x | +73.58% |
| 1996-12-31 | $6.40 Million | $-3.20 Million | -0.500x | +73.66% |
| 1995-12-31 | $4.90 Million | $-9.30 Million | -1.898x | -102.80% |
| 1994-12-31 | $15.60 Million | $-14.60 Million | -0.936x | -7.18% |
| 1993-12-31 | $28.40 Million | $-24.80 Million | -0.873x | -1517.79% |
| 1992-12-31 | $35.20 Million | $-1.90 Million | -0.054x | +67.61% |
| 1991-12-31 | $51.60 Million | $-8.60 Million | -0.167x | -50.29% |
| 1990-12-31 | $51.40 Million | $-5.70 Million | -0.111x | -- |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-pack… Read more